Everest gets Chinese approval for Xerava to treat cIAI
With this approval, the firm intends to introduce Xerava in the Chinese market in the third quarter of this year. Xerava is a new fully synthetic, broad-spectrum, fluorocycline
The US Food and Drug Administration has granted fast track designation to Prestige Biopharma’s PBP1510 (Ulenistamab) to treat unresectable or metastatic pancreatic adenocarcinoma (PDAC).